Prediction Markets Weekly: Kalshi's Biggest Launch Yet, Insider Betting Scandal & Clarity Act Odds

Prediction markets are changing fast, outpacing both regulation and understanding. This week's headlines cut across science, governance, regulatory enforcement, platform economics, user incentives, and everything in between. In this article, I break down five developments, explain how the affected markets work, and speculate on their likely impact. I also name which update matters most.

Kalshi + AppliedXL Launch Clinical-Trial Markets

Prediction market operator Kalshi has partnered with event company AppliedXL to launch markets tracking outcomes of late-stage clinical trials and related FDA decisions. The markets track fixed events based on key information to be released publicly on a fixed timeline. Markets resolve on binary outcomes tied to public filings or official FDA announcements. While Kalshi has previously supported markets tracking various sports and economic data, these are the first prediction markets focused on hard science.

Hard-science prediction markets offer valuable insights that are hard to obtain elsewhere and improve the quality of signals flowing through prediction markets. This likely increased institutional and retail interest; some biotech investors, hedge funds, and pharmaceutical researchers (and their consultants) will find the prices useful for hedging and information discovery. Successful traders will have an advantage over laypeople reading press releases, thanks to a basic trading edge that comes from monitoring sources such as clinicaltrials.gov, public SEC filings, and reports about adverse drug experiences in FDA's MedWatch program.

Even for those without a science background, these markets appear more undervalued than previous public markets, likely because their resolution events are clearer and more objective than, say, whether a presidential candidate wins their party nomination. This will be a shot in the arm for prediction markets and may have applications even beyond healthcare. But there are also regulatory concerns, starting with privacy and possible insider-trading issues. This pilot's reliance on public regulatory announcements will be critical for the market to function in a wide-open marketplace with no restrictions on who can participate. As with most speculative markets, these clinical-trial markets are perfectly legitimate so long as their resolution is based on a single objectively quantifiable outcome that appears in the public domain.

Teleprompter Operator Bets With Insider Information

Federal regulators confirmed that a former White House teleprompter operator placed bets on words used in presidential speeches and made tens of thousands doing so. Regulators are interested in the boundaries around who has access to privileged information, but this particular scenario is fairly straightforward: The teleprompter operator had privileged access to unreleased speeches.

This asymmetry between market participants is not unlike trading on non-public corporate news and moves the needle in a way that damages public trust in prediction markets and their operators. It also risks high-profile legal action against the private actor and the platform for enabling insider trading. This seems unlikely, but the regulators' willingness to pursue privileged actors is clear, and platforms may take note. Expect tighter user IP/insider trading policies, with added categorical bans and more detailed attestations that the bettor has no privileged access. Regardless of the final policy, traders should avoid any betting strategies that depend on privileged access.

Kalshi Donates $2M to Trader Safety

Prediction market operator Kalshi announced a $2 million donation to the National Council on Problem Gambling to fund research, education, and tools aimed at preventing addictive behaviors and promoting responsible gaming. While the donation is generous and well-intentioned, it's also a smart move for responsible growth. This simply removes regulatory friction by giving regulators a solid, official signpost that the operator is committed to responsible gaming.

The funding will likely support educational resources for new users; tools that support self-exclusion, deposit limits, cool-off timers, loss alerts; and research into behavioral triggers. Beyond these initiatives, we'd also expect platform-level features that help users with self-regulation, such as deposit limits, cool-off timers, loss alerts, and others. Whether these features help meaningfully depends on the concrete rollouts, and we'll monitor for transparency around Kalshi's approach and outcomes.

Polymarket Clarity Act Odds Drop to 32%

Polymarket traders have moved the implied probability of Congress passing the Clarity Act down to 32%. That's a rough estimate of a one-in-three chance Congress will pass the legislation protecting against most prediction market activity considered gambling. These odds came after responses to committee hearings, lobbying, floor schedules, and other signals of bipartisan support for the bill.

Kash Introduces Leaderboard Prizes

Prediction market operator Kash today launched a weekly incentive program offering up to $5,000 in prizes to the top 200 players on its leaderboard. Like leaderboards everywhere, prizes not only pay for participation but incentivize user behavior, driving short-term volume and liquidity. But like leaderboards everywhere, they also risk skewing prices due to gamified behavior.

In Summary

Kalshi's clinical-trial market pilot with AppliedXL is the standout development of the week. I've already discussed the unique, exciting, and potentially transformative qualities of this pilot. But here's the short version: Clinical endpoints are high-quality forecasting targets. They're extremely verifiable and consequential well beyond the realm of predictive gambling. The sheer fact that any money would be staked on them in this market has signal value. If institutional money and pharma researchers also use this market, then it grows in size and informational efficiency. It's a potentially scalable use case, already providing a template for prediction markets to become broadly useful and valuable across many drugs and indications. If done right, the clear, transparent rules for public resolution that Kalshi has proposed reduce regulatory ambiguities and provide positive optics for the industry.